SNS-032
Potent and Selective Inhibitor of CDK 2, 7, and 9 for B-cell Malignancies
SNS-032 is a potent and selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9. SNS-032 blocks both the deregulated proliferation of malignant cells by inhibiting CDKs 2 and 7, and the transcription of key survival factors by inhibiting CDKs 7 and 9. See the SNS-032 mechanism of action.
SNS-032 is being studied as a potential therapeutic for B-cell malignancies such as chronic lymphocytic leukemia and multiple myeloma, diseases where survival factors are understood to be critical to interactions between the malignant cell and the microenvironment that sustain these cancers.
SNS-032 Presentations
A Phase 1 Trial of SNS-032, A Potent and Specific CDK 2, 7 and 9 Inhibitor, In Chronic Lymphocytic Leukemia and Multiple Myeloma2008 American Society of Hematology Meeting and Exposition (ASH)
San Francisco, California
December 7th, 2008
A PHASE 1 TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9 INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA13th EHA Congress
Copenhagen, Denmark
June 14th, 2008
SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7 and 9, blocks transcription of cyclin D1 and Mcl-1, causing cell death in mantle cell lymphoma cell lines2008 AACR Annual Meeting
San Diego, CA
April 13th, 2008
Learn more about SNS-032 in clinical trials
Learn about SNS-314, an inhibitor of Aurora kinases A, B, and C
Get general information about clinical studies, and learn about Sunesis investigational drugs currently in clinical trial.
Sunesis researchers rely on science to target new and important ways of treating cancer.
Copyright © Sunesis Pharmaceuticals, Inc. 2007. All Rights Reserved.